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The aim of this study was to assess the in vivo effects of the extract of the medicinal mushroom, Lactarius deterrimus, when
administered (60mg/kg, i.p.) daily for four weeks to streptozotocin- (STZ-) induced diabetic rats. Diabetic rats treated with the L.
deterrimus extract displayed several improved biochemical parameters in the circulation: reduced hyperglycemia, lower triglyceride
concentration and reduced glycated hemoglobin, glycated serum protein, and advanced glycation end product (AGE) levels. This
treatment also adjusted the diabetes-induced redox imbalance. Thus, higher activities of the antioxidative enzymes, superoxide
dismutase, and catalase in the circulation were accompanied by increased levels of free intracellular thiols and glutathionylated
proteins after treatment with the L. deterrimus extract. In addition to a systemic antioxidant effect, the administration of the
extract to diabetic rats also had a positive localized effect on pancreatic islets where it decreased AGE formation, and increased
the expression of chemokine CXCL12 protein that mediates the restoration of 𝛽-cell population through the activation of the
serine/threonine-specific Akt protein kinase prosurvival pathway. As a result, the numbers of proliferating cell nuclear antigen-
(PCNA-) and insulin-positive 𝛽-cells were increased. These results show that the ability of the L. deterrimus extract to alleviate
oxidative stress and increase 𝛽-cell mass represents a therapeutic potential for diabetes management.
1. Introduction
Diabetes mellitus (DM) is a metabolic disorder caused by
absolute insulin deficiency or insufficient insulin secretion
and/or insulin sensitivity [1] and is characterized by hyper-
glycemia. Pancreatic 𝛽-cells are responsible for insulin pro-
duction and maintenance of blood glucose concentrations
[2]. 𝛽-cell dysfunction and declining 𝛽-cell numbers are
responsible for the loss of endocrine pancreas function in
both type 1 (T1D) and type 2 diabetes, albeit loss of 𝛽-
cells is more rapid in autoimmune destruction in T1D.
Hyperglycemia is at the root of the significant increase
in the formation of toxic reactive oxygen species (ROS)
and establishment of oxidative stress that is responsible for
the progression of diabetes and its complications [1], with
vascular injury, hypertension, nephropathy, retinopathy, and
neuropathy as major outcomes.
Despite many strategies and agents, DM management
requires constant improvement. Considering that synthetic
drugs have specific limitations in treating diabetic complica-
tions, it is important to refine approaches based on novel nat-
ural compounds that could support the restoration andmain-
tenance of pancreatic 𝛽-cell numbers and assist in controlling
diabetic complications [3–5]. Since oxidative stress is an
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essential contributor to the development and progression of
diabetes and related complications, the therapeutic approach
to DM is based on improving hyperglycemia and the organ-
ism’s endogenous antioxidant activities. Recent investigations
that have provided evidence for the antidiabetic effectiveness
of mushrooms provide novel approaches for controlling DM
and its complications [6]. Edible mushrooms are rich in
vitamins (B, D, A, C, K), contain high protein contents and
minerals, and are low in saturated fats. Many of the biological
characteristics of mushrooms are mainly due to the presence
of dietary fiber, in particular chitin and the 𝛼 and 𝛽 glucans
that have significant nonspecific immunostimulatory effects
[7, 8]. Mushrooms have also proven to be effective ROS
scavengers, their antioxidant properties correlatingwith their
total content of phenolics [4, 9, 10].
Lactarius deterrimus, also known as false saffronmilkcap,
is an edible mushroom from the family Russulaceae that
mainly grows in coniferous woods in northern, northeast-
ern, and Central Europe. L. deterrimus and other Lactarius
species, such as Lactarius salmonicolor, Lactarius deliciosus,
and Lactarius sanguifluus, possess potentmedicinal activities.
The antimicrobial activities against several Gram (+) and
Gram (−) bacteria and the anticancer and antiviral activi-
ties of their antioxidant constituents have been described;
in addition, it has been suggested that these mushrooms
represent a potential source of natural immunostimulatory
substances [11–13]. Previously, we described the in vitro
antioxidant and scavenging properties of the L. deterrimus
extract, especially NO-scavenging and metal-chelating activ-
ities, which correlatedwith the ability of the extract to prevent
lipid peroxidation and DNA damage during streptozotocin-
induced oxidative stress in Rin-5F cells [14].
The aim of this study was to examine the potential in
vivo beneficial effect of the extract obtained from the edible
mushroom Lactarius deterrimus on the systemic antioxidant
status and control of pancreatic damage in streptozotocin-
(STZ-) induced diabetic rats.
2. Materials and Methods
2.1. Mushroom Collection and Extract Preparation. The
mushroomLactarius deterrimuswas collected near the village
Mune from the Istra region in Croatia in the summer of 2008.
Fruiting bodies were gently cleansed of any residual compost.
Freshmushroomswere air-dried and stored in airtight plastic
bags at room temperature. The dried mushroom samples
were broken up in a blender before extraction with 50%
ethanol at a sample : solvent ratio of 1 : 10 (w/v).The extraction
process was carried out using an ultrasonic bath (B-220;
Branson and SmithKline Company) at 45∘C for 40min. After
filtration, the extraction solvent was removed by a rotary
evaporator (Devarot; Elektromedicina) under vacuum. The
obtained L. deterrimus extracts (Ld) were dried at 60∘C to a
constant mass and stored in glass bottles at −80∘C to prevent
oxidative damage.
2.2. Phytochemical Analysis of the L. deterrimus Extract. The
total phenolic compounds and other oxidation substrates
Table 1: Phytochemical constituents of the L. deterrimus extract.
Phenolic content
(mgGAE/g extract)a
Flavonoid content
(mgQE/g extract)b
Lactarius deterrimus 14.8 ± 2.23 5.07 ± 1.97
Total phenolic and flavonoid contents were determined by the Folin Cio-
calteu and aluminium-chloride colorimetric methods, respectively, and are
expressed as milligrams of gallic acid (GA) per gram of dry mushroom
materiala and as milligrams of quercetin (QE) per gram of dry mushroom
materialb. Data are presented as means ± SD.
contained in dry mushroom extracts were determined by the
Folin-Ciocalteu colorimetric method based on absorbance
at 765 nm [15] and are shown in Table 1. The values are
expressed as g of gallic acid equivalents (GAE) per 100 g
of the dry mushroom extract sample. The total flavonoid
content was analyzed by the aluminum-chloride colorimetric
assay at 510 nm [16] and is expressed as g of quercetin
equivalents (QE) per 100 g of the dry extract sample. Previous
detailed qualitative and quantitative analyses of the extract by
high-performance liquid chromatography with diode-array
detection (HPLC/DAD) revealed the presence of tryptophan,
p-hydroxybenzoic acid, and unsaturated oxy(hydroxyl- or
epoxy-) fatty acids [14].
2.3. Animals. Experiments were performed on 2.5-month-
old adult albino Wistar rats weighing 220–250 g. All animal
procedures were in compliance with the EEC Directive
(86/609/EEC) on the protection of animals used for experi-
mental and other scientific purposes and were approved by
the Ethical Committee for the Use of Laboratory Animals
of the Institute for Biological Research “Sinisˇa Stankovic´”,
University of Belgrade.
2.4. Experimental Design. The experimental model of multi-
ple low dose (MLDS) STZ-induced diabetes was used. Dia-
betes was induced by injection (i.p.) of STZ (40mg/kg/day)
to Wistar rats for five consecutive days. STZ was dissolved
before use in sodium citrate buffer (0.1M, pH 4.5). Blood
glucose was measured 24 h after the last STZ injection.
Blood samples were obtained from the tail vein of rats that
fasted overnight, and glucose was measured with a blood
glucose meter (Accu-Chech Active). Rats were considered to
have diabetes when the fasting blood glucose level exceeded
20mmol/L (the baseline glucose level measured before dia-
betes induction by STZ was 6.2 ± 0.3). Male albino Wistar
rats were randomly divided into four groups: (i) NDM:
the nondiabetic group (𝑛 = 7), also referred to as the
negative control, received citrate buffer (i.p.) equivalent to
the STZ injection for 5 consecutive days; (ii) NDM + Ld:
the nondiabetic group (𝑛 = 7), also referred to as the
positive control, was administered the mushroom extract
(Ld; 60mg/kg, i.p.) daily for four weeks; (iii) DM: the diabetic
group (𝑛 = 8) was injected STZ and left untreated throughout
the fourweek period; (iv)DM+Ld: the diabetic group (𝑛 = 8)
was treated with the Ld daily for four weeks, starting from the
last day of STZ administration.
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2.5. Serum and Hemolysate Preparation. Rat blood serum
was collected after blood clotting and centrifugation at
2000×g for 10min. The serum was used for determi-
nation of glycated proteins and the amounts of protein
sulfhydryl groups (–SH). For the preparation of red blood cell
(RBC) hemolysates, blood was collected in heparinized tubes
(1 000 IU heparin) and centrifuged at 2000×g for 10min.
RBCs were washed twice with 0.9% NaCl and centrifuged.
The washed RBCs were lysed in 3 volumes of cold water for
30min on ice. Hemolysates were used for the determination
of catalase (CAT), superoxide dismutase (SOD), glutathiony-
lated proteins (GSSP), hemoglobin (Hb), and glycated (Gly)
Hb.
2.6. Determination of Biochemical Parameters of Diabetes.
Blood glucose levels were measured with a commercial
kit (Gluco-quant Glucose/HK, Boehringer Mannheim, Ger-
many) based on the hexokinase/G6P-DH enzymatic method.
GlyHb was determined by the colorimetric assay according
to Parker et al. [17]. Serum triglycerides were measured by
the glycerol-3-phosphate (GPO) oxidase-p-aminophenazone
(PAP) method with an enzymatic kit (Randox Laboratories,
UK). Detection of glycated serum proteins was by the
fructosamine assay. The glycation of serum proteins was
measured according to Johnson et al. [18]. Aliquots of sera
(50𝜇L) were added to 450 𝜇L of 100mM carbonate buffer
(pH 10.8) containing 0.5mM nitro blue tetrazolium (NBT).
The samples were incubated for 1 h at 37∘C. Absorbance was
measured at 595 nm.
2.7. Determination of GSSP in the Circulation. Acid-precip-
itated proteins in hemolysates were thoroughly washed with
the precipitating solution until no trace of soluble reduced
glutathione (GSH) or glutathione disulfide (GSSG) was
detected. The pellets were then resuspended and brought
to an alkaline pH (pH 7.5–8) for 5–30min. Under these
conditions, GSH is released via an –SH/disulfide (–S–S–)
exchange reaction. The reaction was stopped by the addition
of trichloroacetic acid to a final 5% concentration. The
amount of releasedGSHwas determined enzymatically in the
supernatants after centrifugation.
2.8. Determination of Protein Sulfhydryl Groups inCirculation.
Protein –SH groups were determined by Ellman’s method
[19]. Briefly, 0.5mL of serum was added to a cuvette con-
taining 0.1M phosphate buffer, pH 7.4 (0.5mL); 0.2mL of
3mM 5,5󸀠-dithiobis (2-nitrobenzoic acid) was then added to
start the reaction. Absorbance was measured at 412 nm after
10min. The number of –SH groups was calculated according
to the following formula:
mol –SH/g proteins
= [
𝐴 sample
14150
× dilution factor] /g proteins.
(1)
2.9. Determination of SOD and CAT Activities in the Circu-
lation. CAT activity was determined according to Beutler
[20] as the rate of hydrogen peroxide decomposition and
expressed as 𝜇mol H
2
O
2
/min/g Hb. The Hb was removed
from hemolysates prior to measurement of SOD activity by
the epinephrine method [21]. One unit of SOD activity was
defined as the amount of Hb that causes 50% inhibition of
adrenaline autoxidation.
2.10. Determination of AGE in Circulation. The fluorescent
products of AGE were detected according to Munch et al.
[22], Henle et al. [23], and Kalousova´ et al. [24]. Blood serum
was diluted 1 : 50 with phosphate buffered saline (PBS) pH
7.4 and fluorescence intensity was measured at an excitation
wavelength of 350 nm and an emission wavelength of 440 nm
with a luminescence spectrometer (LS50B; Perkin-Elmer
Ltd., Buckinghamshire, England). The fluorescence intensity
was expressed in arbitrary units.
2.11. Histological Analysis and Immunostaining. The pancre-
ata from all experimental groups were removed and fixed
in 10% buffered formalin for histological and immunohis-
tological examination. Pancreatic tissues from all examined
groups were blocked in paraffin and sectioned at 5𝜇m thick-
ness for histological and immunohistochemical examination
(Leica DMLB; objective magnification 40x). For histological
analysis tissue sections were stained with hematoxylin and
eosin and observed under a light microscope. For immuno-
histochemical analysis, deparaffinized sections were passed
through xylene and rehydrated in sequentially graduated
ethyl alcohol. Slides were incubated in 0.3% hydrogen perox-
ide/methanol for 20min to reduce nonspecific background
staining due to endogenous peroxidase. After washing in
PBS, the sections were treated with 0.01M sodium citrate
buffer at 98∘C for antigen retrieval. The cooled tissues
were washed four times in PBS prior to application of the
blocking serum for 5min (0.05% Tween 20, 5% bovine
serumalbumin).Theprimary antibodywas applied overnight
at room temperature (RT). Polyclonal antibodies raised
against insulin, CXCL12, C-X-C chemokine receptor type 4
(CXCR4), N(𝜀)-(carboxymethyl)lysine (CML), an advanced
glycation end product (AGE), receptor for AGE (RAGE),
phosphorylated protein kinase B (pAkt), andproliferating cell
nuclear antigen (PCNA) (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) were diluted 1 : 50 in PBS with 2% dry
skimmedmilk. Afterwashing in PBS, sectionswere incubated
at RT for 1 h with secondary antibody horseradish peroxidase
(1 : 100) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Tissues were incubated for 20min at RT in a solution of
3,3󸀠-diaminobenzidine (DAB). After washing with PBS, the
tissueswere counterstainedwith haematoxylin andwashed in
water, and the coverslips were applied with mounting media.
For the negative control, the primary antibody was not added
to the sections.
2.12. Statistical Analysis. Thedatawere expressed as themean
± S.E.M. (standard error of mean). Statistical differences
between groups were analyzed using one-way analysis of
variance (ANOVA), followed byDuncan’smultiple range test.
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Figure 1: The effect of L. deterrimus extract administration on the biochemical parameters in sera (a) and glycation levels of serum proteins
(b). NDM: control rats; NDM + Ld: control rats treated daily with L. deterrimus extract for four weeks; DM: STZ-induced diabetic rats; DM
+ Ld: STZ-induced diabetic rats treated with L. deterrimus extract for four weeks. Hb: haemoglobin. The values are presented as the mean ±
S.E.M.; values not sharing a common superscript letter differ significantly at 𝑃 < 0.05.
The difference was considered statistically significant at 𝑃 <
0.05.
3. Results
3.1. Biochemical Parameters of Diabetes in Rats Treated with
the L. deterrimus Extract. Administration of Ld led to an
overall improvement of the main biochemical parameters of
diabetes, albeit short of their restoration to their respective
physiological levels. As can be seen in Figure 1(a), treatment
of diabetic animals with Ld reduced the glucose concentra-
tion by almost 25% and lowered the level of triglycerides
by about 28% and GlyHb by about 21%. The treatment also
lowered the level of serum protein nonenzymatic glycation
to the level measured in control rats (Figure 1(b)). Ld-
treated nondiabetic rats did not exhibit any changes of these
parameters when compared to the control group.
3.2. Oxidative Stress and Antioxidative Protection in the
Circulation of Rats Treatedwith the L. deterrimus Extract. The
redox status in experimental rats was estimated bymeasuring
the levels of free intracellular thiols (Figure 2(a)) and GSSP
(Figure 2(b)) that are directly linked to the redox state of the
cell [25, 26]. These experiments revealed that the treatment
with Ld significantly improved the redox parameters in the
circulation. While the level of serum protein –SH groups was
significantly decreased in diabetic rats, the treatment with Ld
restored the –SH content almost to the control level.The –SH
content was not significantly changed when control rats were
administered the extract. As can be observed in Figure 2(b),
the 1.3-fold increase in the level of GSSP in diabetic rats as
compared to the control level was brought to the control
level by the administration of Ld. The GSSP level was not
significantly changed when healthy rats were administered
Ld.
The activities of the major antioxidant enzymes, SOD
and CAT, provide the first line of antioxidant defenses and
protect cells from ROS damage [27]. As can be seen in
Figure 2(c), the decreased levels of SOD and CAT activities
in the circulation of diabetic rats were improved after Ld
administration, the effect of Ld being more pronounced
on CAT activity. In addition, a significant increase in the
SOD/CAT ratio was observed under diabetic conditions,
while the Ld treatment reduced this ratio to the control level
in diabetic animals. SOD and CAT activities did not change
after Ld administration to control rats.
3.3. L. deterrimus Extract Administration Induces Histolog-
ical Changes and Stimulates the Production of Insulin and
CXCL12 in Pancreatic Islets. Hematoxylin and eosin sections
(Figure 3) show that the pancreas of control rats is comprised
of numerous, compactly arranged cells in the islets of Langer-
hans that appear as dense cords. The pancreas of diabetic
rats had smaller pancreatic islets with lower numbers of 𝛽-
cells, displaying increased vacuolation and clumped cells. Ld-
treated diabetic rats resembled more closely normal islet cell
architecture, which is suggestive of a protective role of Ld
on the pancreas of diabetic rats (Figure 3, HE). Immunohis-
tochemical staining with insulin revealed disorganized islets
in diabetic rats, with unevenly distributed insulin-positive
cells in comparison to control islets that displayed strong
insulin immunostaining (Figure 3, insulin).The Ld treatment
increased the number of insulin-positive cells in the islets of
diabetic rats (Figure 3, insulin).
The chemokine CXCL12 and its receptor, CXCR4, have
been shown to mediate 𝛽-cell repair [28]. Immunohisto-
chemical staining revealed the presence of CXCL12-positive
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Figure 2:The effect of L. deterrimus extract administration on the content of free –SH (a), level of protein bound glutathione (GSSP) (b), and
activities of antioxidative enzymes (c) in the circulation. NDM: control rats; NDM + Ld: control rats treated daily with L. deterrimus extract
for four weeks; DM: STZ-induced diabetic rats; DM + Ld: STZ-induced diabetic rats treated with L. deterrimus extract for four weeks. The
values are presented as the mean ± S.E.M.; values not sharing a common superscript letter differ significantly at 𝑃 < 0.05.
cells only in diabetic islets and their increased presence
in islets from Ld-treated rats. As can be seen in Figure 3,
CXCR4-positive immunostaining was only detected in the
islets of diabetic rats.
3.4. The Effects of the L. deterrimus Extract Administration on
CML-Modified Proteins in Pancreatic Islets. Chronic hyper-
glycemia causes tissue damage that is mediated in part by
the nonenzymatic glycation and oxidation of proteins and
lipids and the formation of AGE of which CML is one of the
most often usedmarkers [29]. AGE exert their effects through
interactions with their receptor RAGE that is normally
expressed at low levels on the surface of most cell types. In
addition to the circulation, AGE accumulate in tissues where
they contribute to the development of diabetic complications.
In the pancreas they play a part in progressive 𝛽-cell loss
[30]. Determination of the fluorescent products of AGE in the
serum revealed a 1.5-fold increase in AGE in diabetic rats. In
diabetic rats administered Ld, the increase in AGE was at the
control level (Figure 4(a)). Immunohistochemical staining
revealed an extensive distribution ofCML-positive cells in the
islets of diabetic rats. In Ld-treated diabetic rats, the CML-
positive cells were more disperse (Figure 4(b), CML). RAGE
was observed only in the islets of diabetic rats (Figure 4(b),
RAGE).
3.5. The Effects of L. deterrimus Extract Administration on
the Prosurvival and Proliferative Pathways in Pancreatic Islets.
Phosphoinositide 3-kinases (PI3Ks) and its downstream
effector protein kinase Akt mediate cellular survival signals
that have an essential function in pancreatic 𝛽-cell survival
[31]. Immunohistochemical staining with activated pAkt
shown on Figure 5 revealed its presence in the islets of
both control groups, whereas in diabetic islets pAkt-positive
staining was weaker. Treatment of diabetic animals with Ld
caused a considerable increase in pAkt staining that points to
the stimulation of the prosurvival pathway in islets.
Immunohistochemical staining with PCNA (Figure 5),
which assumes an essential function in DNA replication
and repair, revealed its extensive distribution in the nuclei
of islets of both control groups. However, in the islets of
diabetic animals, no PCNA immunostaining was detected.
The Ld-treated diabetic rats exhibited PCNA staining in
their islets (Figure 5, PCNA). The increased presence of
PCNA in Ld-treated diabetic rats points to the activation
of proliferative mechanisms, which is in agreement with the
described stimulation of the prosurvival pathway.
4. Discussion
In this report we have presented evidence for the beneficial
effect of the daily i.p. administration for four weeks of the
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Figure 3: The effect of administration of the L. deterrimus extract on histological changes and immunohistochemical localization of insulin
and CXCL12 in pancreatic islets. HE: hematoxylin and eosin staining of pancreatic sections; light photomicrographs of insulin, CXCL12, and
CXCR4 immunohistochemical staining of pancreatic sections within islets (magnification 40x). NDM: control rats; NDM + Ld: control rats
treated daily with L. deterrimus extract for four weeks; DM: STZ-induced diabetic rats; DM + Ld: STZ-induced diabetic rats treated with L.
deterrimus extract for four weeks.
extract of Lactarius deterrimus (Ld) to STZ-induced diabetic
rats. This was manifested as improved hyperglycemia and
a resulting decline in GlyHb, serum protein glycation, and
decreased formation of AGE in the circulation, as well as
lower triglyceride concentrations. We interpret these global
changes as part of a systemic antioxidant effect that impacted
pancreatic islets in diabetic rats. By suppressing the formation
and accumulation of potential inducers of 𝛽-cell damage
in diabetic rats (detected as a decrease in CML-containing
species in the pancreas), Ld administration activated prosur-
vival CXCL12/Akt signaling and the proliferative pathway,
observed as the increased presence of PCNA-containing 𝛽-
cells.Therefore, by shifting the balance of𝛽-cell death in favor
of 𝛽-cell survival, the net result of Ld administration was an
increase in the number of functional insulin-positive 𝛽-cells.
High concentrations of ROS are involved in pathological
changes of cellular functions and disruptions of cellular
homoeostasis [1]. In diabetes, persistent hyperglycemia
causes enhanced glucose autooxidation and protein glycosy-
lation that increase the production of ROS that are important
agents in the development of diabetic complications. The
lower activities of the antioxidant enzymes CAT and SOD,
along with the decreased protein –SH content and increased
amounts of GSSP moieties, serum protein glycation, and
GlyHb, revealed the presence of oxidative stress in the
circulation of diabetic rats. After the four-week treatment
of diabetic rats with Ld, these parameters were practically
restored to their physiological values. Ld administration
caused a significant decrease in the SOD/CAT ratio that was
associated with lower hydrogen peroxide levels, decreased
oxidative stress. This shows that the administration of Ld
under diabetic conditions attenuated the oxidative stress-
induced harmful processes by improving hyperglycemia and
promoting increased activities of antioxidative enzymes.
Journal of Diabetes Research 7
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Figure 4: The effect of L. deterrimus administration on AGE in the circulation (a) and presence of CML-modified proteins in pancreatic
islets (b). Fluorescent products of AGE in the serum (a). Light photomicrographs of immunohistochemical staining for CML and RAGE
of pancreatic sections within the islet (b) (magnification 40x). NDM: control rats; NDM + Ld: control rats treated daily with L. deterrimus
extract for four weeks; DM: STZ-induced diabetic rats, DM + Ld: STZ-induced diabetic rats treated with L. deterrimus extract for four weeks.
The values are presented as the mean ± S.E.M.; values not sharing a common superscript letter differ significantly at 𝑃 < 0.05.
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Figure 5: The effect of L. deterrimus extract administration on the prosurvival pathway and 𝛽-cell proliferation in pancreatic islets. Light
photomicrographs of immunohistochemical staining for pAkt and PCNA of pancreatic sections within the islet (magnification 40x). NDM+
Ld: control rats treated daily with L. deterrimus extract for four weeks; DM: STZ-induced diabetic rats; DM + Ld: STZ-induced diabetic rats
treated with L. deterrimus extract for four weeks.
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These results are consonant with literature data showing
that edible mushrooms possess antioxidant and free radical
scavenging properties [3]. The Ld applied herein is enriched
in both phenolics and flavonoids that contributed to its free-
radical scavenging activity (Table 1) [14]. This assumption is
in agreement with the generally held view that the antiox-
idant properties of mushroom extracts correlate with their
total content of phenolics [10] and with Wang and Xu [5]
who recently provided additional evidence that phenols and
polyphenols are the major naturally occurring antioxidant
compounds in wild edible mushrooms.We speculate that the
free radical scavenging activity of Ld could also be attributed
to 𝛽-glucan, a principal component of mushrooms known
to play important roles in the activation of the nonspecific
immune response, reduction of blood cholesterol and blood
glucose concentrations, protecting blood macrophages from
ionizing radiation, and restoring bone marrow production
[5, 32, 33]. Results fromour previousworkwith plant-sourced
𝛽 glucan revealed its ability to cause a systemic adjustment
of redox disturbance and to exert a beneficial effect under
diabetic conditions via its antioxidant and anti-inflammatory
activities [34, 35].
AGE also play a role in toxic signaling in diabetic pathol-
ogy by contributing to unbalanced free-radical formation
and activating stress signaling in cells through interactions
with RAGE. AGE are caused by glycation that involves
a series of nonenzymatic reactions between the carbonyl
group on reducing sugars and the amino group on proteins
[36]. The classical pathway of AGE formation involves a
glucose-protein condensation reaction to form Schiff base
adducts that undergo Amadori rearrangement [37].The early
glycosylation products accumulate predominantly on long-
lived proteins that undergo a series of in vivo rearrangements
to form irreversible compounds and a number of reactive
intermediates that enhance oxidative stress [38]. Our results
describe a significant increase in serum AGE in diabetic rats
and their reversion to the control level after the Ld treatment.
Through the generation of ROS and reactive nitrogen species,
AGE contribute to tissue injury by changing the structure
and function of proteins, thereby affecting important cellular
functions, either directly or via RAGE-activated pathways
[39]. In addition to AGE in the circulation, we established
the presence of CML, the most abundant AGE in vivo, and
of RAGE in pancreatic islets of diabetic rats. Importantly,
in pancreatic islets of Ld-treated diabetic animals, CML was
barely detectable and RAGE was undetectable by the experi-
mental procedure applied herein. AGE generally accumulate
in tissues that display diabetic complications [24, 40]. Lee
and coworkers [30] have demonstrated that the interaction
betweenAGEandRAGEcontributes to the progressive loss of
𝛽-cells in diabetes through intracellular ROS generation.This
finding and our results indicate that the 𝛽-cells of Ld-treated
diabetic rats were exposed to a lower level of toxic signals than
𝛽-cells of diabetic rats.
The efficacy of medicinal mushrooms in the treatment
of diabetes by protecting against 𝛽-cell damage through
enhanced antioxidant defenses, reduced inflammation, and
increased insulin release has been reported [6, 41, 42]. The
results obtained herein by immunohistological examination
of the pancreas revealed that Ld administration to diabetic
rats restrained islet destruction and partially restored the
number of insulin-positive cells. The activation and direct
involvement of the chemokine CXCL12/CXCR4 receptor pair
in cardiomyocytes and pancreatic islets have been demon-
strated after tissue injury [43, 44], the latter authors showing
increased CXCR4 mRNA and protein expression in insulitis.
Recently it was established that injury of 𝛽-cells induces
CXCL12 expression that initiates the transdifferentiation of
𝛼-cells to 𝛽-cells in the pancreas [45]. PI 3-kinase and the
downstream effector protein Akt play key roles in mediating
signals for cell growth, cell survival, cell-cycle progression,
and differentiation [31, 46]. Activated, phosphorylated Akt
by insulin and growth factors is implicated in glucose
metabolism, transcriptional control, and mediation of anti-
apoptotic and prosurvival events in 𝛽-cells [47, 48]. Yano
et al. [49] described the important function of CXCL12 in
diabetes attenuation in mice via promotion of 𝛽-cell survival
by Akt activation. The functions of CXCL12 described in
the literature suggested to us that the increased presence
of CXCL12 stimulated the Akt pathway, affecting elevated
expression of PCNA protein in Ld-treated diabetic rats. This
result indicates that Ld exerted a stimulatory effect on islet
proliferation and regeneration. Considering the significant
capacity of the endocrine pancreas to adjust to changes
in insulin demand [50], and that the pancreas contains
quiescent cells that can proliferate and replace lost cells [51],
we believe that the described stimulatory activity of Ld can
exert an important beneficial effect during the initial stage
of diabetes development when it is potentially possible to
expand the still existing 𝛽-cell mass through regeneration.
Pancreatic 𝛽-cell regeneration induced by 𝛽-cell proliferation
is often mentioned as a vital goal in the development of
effective treatments for diabetes [52]. The findings described
herein point to the possibility of developing the therapeutic
potential of Lactarius deterrimus in diabetes management by
employing its ability to alleviate oxidative stress and increase
𝛽-cell mass.
5. Conclusion
In vivo antioxidant and antidiabetic effects of the extract from
the mushroom Lactarius deterrimus were determined. Our
results show that administration of the extract to diabetic rats
restores antioxidant enzyme activities in the circulation and
decreases oxidative stress. Treatment with the extract exhibits
a potential for preserving pancreatic islet structure and
increasing 𝛽-cell mass through activation of the prosurvival
CXCL12/Akt pathway and stimulation of 𝛽-cell proliferation.
We believe that the effects of the mushroom extract are
important as it is derived from an established food used for
human consumption. However, as a caveat to these findings,
the described potentially positive effects have to be proven in
human diabetics, and any side effects from prolonged extract
administration as described herein need to be assessed.
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